Testing new pre-surgery treatment for locally advanced rectal cancer
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial compares a pre-surgery (neoadjuvant) treatment plan versus the standard plan for people with stage II–III rectal cancer. The goal is to see which approach works better and is safe before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rectal adenocarcinoma (a type of rectal cancer).
- Your tumor can be measured on scans, and it is stage II or III based on pelvic MRI/ultrasound.
- There is no sign that the cancer has spread to distant organs on CT scans of the chest and abdomen.
- The tumor is located within 0 to 15 cm from the anus, as checked during a proctoscopy.
- You are well enough to take part (general condition score of 0–2).
- Your recent blood tests and organ function (kidneys/liver) are in a safe range, and you can provide pregnancy test (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a full course of chemotherapy and radiation before any surgery (called total neoadjuvant therapy) can help you avoid surgery and preserve your rectum. It is for people with a specific early stage of rectal cancer that has not spread.
This trial tests a combination of chemotherapy and radiation therapy before surgery for people with mid or low rectal cancer that hasn't spread. The goal is to see if this approach works better than current treatments.
This trial tests a new combination of standard chemotherapy, immunotherapy (a drug that helps your immune system fight cancer), and a special diet and/or high-dose vitamin C before surgery for rectal cancer. It aims to shrink the tumor and improve surgery outcomes.
This trial compares different combinations of chemotherapy drugs given before surgery to the standard approach of chemoradiation (chemotherapy plus radiation) for rectal cancer that has not spread. The goal is to see if the drug combinations are more effective at shrinking tumors and improving outcomes.
This trial compares two different chemotherapy combinations given before radiation or surgery for high-risk locally advanced rectal cancer. One arm is more intense, and the other is standard. The goal is to see which works better at shrinking the tumor and possibly avoiding surgery.
This trial tests whether combining chemotherapy (mFOLFOX6) and a short course of radiation before surgery improves outcomes for people with resectable rectal cancer. The goal is to shrink and control the cancer early and then remove it with curative surgery.
Hear when a new Neoadjuvant Therapy in Rectal Cancer, Radiotherapy, FOLFOX trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.